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Abstract
Purpose The human monoclonal antibody (MAb) fragment
L19-SIP is directed against extra domain B (ED-B) of
fibronectin, a marker of tumour angiogenesis. A clinical
radioimmunotherapy (RIT) trial with
131I-L19-SIP was
recently started. In the present study, after GMP production
of
124I and efficient production of
124I-L19-SIP, we aimed to
demonstrate the suitability of
124I-L19-SIP immuno-PET for
imaging of angiogenesis at early-stage tumour development
and as a scouting procedure prior to clinical
131I-L19-SIP
RIT.
Methods
124I was produced in a GMP compliant way via
124Te(p,n)
124I reaction and using a TERIMO™ module for
radioiodine separation. L19-SIP was radioiodinated by
using a modified version of the IODO-GEN method. The
biodistribution of coinjected
124I- and
131I-L19-SIP was
compared in FaDu xenograft-bearing nude mice, while
124I PET images were obtained from mice with tumours
of <50 to ∼700 mm
3.
Results
124I was produced highly pure with an average
yield of 15.4±0.5 MBq/μAh, while separation yield was
∼90% efficient with <0.5% loss of TeO2. Overall labelling
efficiency, radiochemical purity and immunoreactive fraction
were for
124I-L19-SIP: ∼80 , 99.9 and >90%, respectively.
Tumour uptake was 7.3±2.1, 10.8±1.5, 7.8±1.4, 5.3±0.6
and 3.1±0.4%ID/g at 3, 6, 24, 48 and 72 h p.i., resulting in
increased tumour to blood ratios ranging from 6.0 at 24 h to
45.9 at 72 h p.i.. Fully concordant labelling and biodistribu-
tion results were obtained with
124I- and
131I-L19-SIP.
Immuno-PET with
124I-L19-SIP using a high-resolution
research tomograph PET scanner revealed clear delineation
of the tumours as small as 50 mm
3 and no adverse uptake in
other organs.
Conclusions
124I-MAb conjugates for clinical immuno-PET
can be efficiently produced. Immuno-PET with
124I-L19-SIP
appeared qualified for sensitive imaging of tumour neo-
vasculature and for predicting
131I-L19-SIP biodistribution.
Keywords PETimaging.L19-SIP.ExtradomainB
offibronectin.Angiogenesis.Radioimmunotherapy
Introduction
Angiogenesis is one of the hallmarks of cancer, and
therefore, considerable efforts have been made recently to
image as well as to eradicate tumour vasculature, preferably
in a combined fashion [1, 2]. One of the appealing targets
for both approaches is the splice variant of fibronectin
containing extra domain B (ED-B). ED-B is abundantly
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cancers, primary tumours as well as metastases [3–6].
Interestingly, ED-B is undetectable in normal tissues, with
the exception of tissues undergoing physiological modelling
(e.g. endometrium and ovary) and during wound healing [3].
This target is highly conserved in different species, having
100% homology in many mammalian species (e.g. human,
rat, mouse), and therefore making proof of principle studies
in tumour-bearing mice of special relevance [7].
Recently, a human recombinant scFv fragment directed
against ED-B, designated L19, was developed [8]. Using its
variable regions, several other L19 formats were constructed,
including dimeric scFv [(scFv)2], a human bivalent “small
immunoprotein” (SIP, ∼80 kDa), and a complete human
IgG1 [9]. Radiolabelled L19 constructs have been evaluated
in tumour-bearing nude mice to identify the most appropriate
conjugate for radioimmunotherapy (RIT) of solid tumours
[9–12]. To this end, the L19 derivatives were labelled with
125Io r
111In [10]. The resulting biodistribution data were
used to perform dosimetry for the corresponding therapeutic
counterparts labelled with
131Ia n d
90Y, respectively, and to
select a conjugate for clinical RIT. The most favourable
therapeutic index was found for
131I-L19-SIP, while this
index was a poor one for
90Y-labelled derivatives [10]. RIT
with
131I-L19-SIP at maximum tolerated dose caused
significant tumour growth delay and improved survival in
several animal models [10–12].
On the basis of the aforementioned bright perspectives, a
clinical RIT trial with
131I-L19-SIP was designed [13]. This
trial comprises the selection of RIT candidate patients on
the basis of pretherapy SPECT imaging and dosimetry.
Rationales for this approach are the variable ED-B
expression in tumours, with higher expression in the more
aggressive ones, and the potential occurrence of ED-B
expression in normal tissues.
We and others recently proposed immuno-PET as a high-
resolution quantitative imaging procedure before or concom-
itant with RIT to improve confirmation of tumour targeting
and to assess radiation dose delivery to both tumours and
normal tissues [14–16]. Important in such approach is the
choice of the positron emitting radionuclide to be used for
radiolabelling. Among others, its physical half-life (t1/2)
should be compatible with the time needed for a MAb to
achieve optimal tumour to non-tumour ratios, being >24 h for
L19-SIP. In addition, when immuno-PET is used for selection
of RIT candidates, the radioimmunoconjugates used for
immuno-PET and RIT should demonstrate a similar biodis-
tribution, and therefore, by preference, radionuclides with
comparable in vivo behaviour must be used. The starting
positron emitter solution should meet appropriate radiophar-
maceutical quality standards when used for clinical purposes.
The halogens
76Br (t1/2=16.2 h) and
124I( t 1/2=4.18 d)
are promising candidate positron emitters for L19-SIP
immuno-PET in combination with
131I-L19-SIP RIT;
however, availability of GMP-compliant material is a
problem for both. Rossin et al. [17] recently described
76Br-L19-SIP for imaging of tumour neovasculature in
xenograft-bearing nude mice. While tumour uptake of
76Br-L19-SIP was high, a disadvantage was the long
retention of radioactivity in blood and the very slow renal
excretion. As a consequence, the background activity in non-
target organs was higher than that reported for
125I-labelled
L19-SIP, and this resulted in lower target to non-target ratios.
Taking the aforementioned aspects into account, we
hypothesized that
124I-L19-SIP might be the most optimal
candidate for immuno-PET imaging of tumour neovascula-
ture, and for prediction of biodistribution and dosimetry of
131I-L19-SIP in RIT. Although the choice of
124I-L19-SIP
immuno-PET seems logical, no such studies have been
reported as yet, and several technical hurdles had to be
taken to enable future clinical evaluation. For this purpose,
and to facilitate the translation to clinical application, we
developed the production and purification of
124I in a GMP-
compliant setting, and its coupling to L19-SIP, with the aid
of IODO-GEN. With respect to the latter, procedures were
established for efficient coupling of no-carrier-added
124I.
124I-L19-SIP was evaluated by comparison of biodis-
tribution with
131I-L19-SIP upon coinjection in xenograft-
bearing nude mice and by imaging of mice with tumours of
<50 to ∼700 mm
3 with a high-resolution research tomograph
(HRRT) PET scanner.
Materials and methods
Monoclonal antibody, xenograft line and radioactivity
Antibody L19-SIP (conc. 1.23 mg/ml), directed against the
ED-B domain of fibronectin, was obtained from Bayer
Schering Pharma, Berlin, Germany. Selection, construction
and production of L19-SIP (MW=∼80 kD) have been
described previously [8, 9]. The MAb cetuximab (Erbitux®
conc. 2.0 mg/ml) was used as reference for optimization of
124I labelling and was purchased from Merck, Darmstadt,
Germany.
The human HNSCC cell line FaDu has been described
before [18], was obtained from KH Heider (Boehringer
Ingelheim Austria), and has been characterized for ED-B
expression [11].
131I (66.4 GBq/ml; specific activity 611 GBq/mg) was
purchased from Perkin Elmer.
124I production and quality tests
124I was produced at BV Cyclotron VU (Amsterdam, The
Netherlands) via a
124Te(p,n)
124I reaction and isolated by
1236 Eur J Nucl Med Mol Imaging (2009) 36:1235–1244use of dry distillation essentially as described by Qaim et al.
[19]. In short, the target consisted of a glassy layer of
124TeO2 (enrichment of 99.8%; Isoflex, San Francisco, CA,
USA) mixed with 5% (w/w) Al2O3. The physical thickness
of the target was 250 mg/cm
2. A platinum (Pt) disc (Ø=
25 mm; thickness=2 mm) containing a cavity (Ø=14 mm;
depth=1 mm) was used as backing. The target was loaded
on an in house made solid target station installed on a IBA
Cyclone 18/9 cyclotron and irradiated with 12.5 MeV
protons using a beam current of up to 20 µA for 2–10 h.
During irradiation, the target was cooled in front using
helium cooling and at the back using water cooling. A
TERIMO module (Elex Commerce, Belgrade, Serbia) was
used for radioiodine separation by dry distillation. Trapping
of
124I was performed in 1 ml 50 mM NaOH.
Assessment of the radiochemical purity of the
124I
preparations was performed by HPLC analysis, using a
L i C h r o s p h e r1 0 0R P - 1 8c o l u m n( 1 2 5 × 4m m ,5µ m ;
Merck). As eluent 0.1 mol/l NaCl/0.004 mol/l octylamine
(pH 7) + 5% (v/v) MeCN was used at a flow rate of 1.5 ml/min.
The HPLC retention times were 1.5 min for IO
3− and 5.0 min
for I
− [20]. For identification and quantification of radio-
nuclidic contaminants a germanium(lithium) [Ge(Li)] detector
was used coupled to a multichannel analyser [21]. The
tellurium content was assessed by a spectrophotometric
method as described by Qui-e et al. [22]. The endotoxin
levels were assessed by use of an FDA-licensed LAL test
system according to the instructions provided by the supplier
(Endosafe®-PTS, Charles River, Charleston, SC, USA).
Autoclaving was not performed but can be used as an option
to assure sterility.
Radiolabelling
Preparation of
124I-L19-SIP Three sets of labelling experi-
ments with L19-SIP were performed within the following
general frame [23]: 20 ml ß-scintillation glass vials were
coated with 25 µg IODO-GEN (Pierce, Rockford, IL, USA)
in dichloromethane, dried under a stream of N2 gas, resulting
in a thin coating of IODO-GEN on the bottom surface of the
vial. The vials were stored under N2 atmosphere. To a
IODO-GEN-coated glass vial, successively 50 µl 0.5 M
Na2HPO4 (pH 7.4), 450-X-Y µl 0.1 M Na2HPO4 (pH 6.8),
X µl L19-SIP and Y µl radioiodine solution were added.
After gentle shaking for 4 min at room temperature, 0.1 ml
ascorbic acid (25 mg/ml, pH 5) was added to reduce the
IODO-GEN and to protect the L19-SIP against radiation
damage. After an additional 5 min, the reaction mixture was
transferred to a syringe connected to a filter (0.22 µm
Acrodisc, Gelman Sciences, Ann Arbor, MI, USA) followed
by 0.4 ml 0.1 M Na2HPO4 (pH 6.8), used for an additional
rinsing of the reaction vial. This combined solution was
filtered and purified on a PD-10 column (GE Healthcare Life
Sciences, Piscataway, NJ, USA) with 0.9% NaCl/ascorbic
acid (5 mg/ml, pH 5) as eluent. The first 2.5 ml (1.0 ml
sample volume and the first 1.5 ml) were discarded and the
radiolabelled antibody was collected in the next 1.5 ml.
In the first set, the
124I labelling efficiency was
optimized by varying the amount of NaI present during
the reaction. In these experiments X was 82 µl (100 µg,
1.33 nmol) L19-SIP, while Y was 50 µl of a series of pre-
equilibrated (5 min)
124I/NaI mixtures, each containing
2.4 MBq
124I and, respectively, 6700, 1675, 838, 419, 209,
105, 52, 26 and 0 pmol NaI. A similar series of labellings
was performed with the control MAb cetuximab, for which
X was 50 µl (100 µg, 0.66 nmol). It is of note that the
2.4 MBq
124I activity used in each reaction in the case of
carrier-free
124I corresponds with 2.1 pmol iodine.
In the second set,
124I-L19-SIP and
131I-L19-SIP were
synthesized for a biodistribution study. The labelling was
carried out with X=163 µl (200 µg, 2.66 nmol) L19-SIP; Y
was 83 µl
124I solution (14.8 MBq, 266 pmol NaI). For
131I,
X was also 163 µl L19-SIP solution, and Y was 2 µl of a
diluted
131I batch (14.8 MBq). No NaI carrier was added to
this solution, because 14.8 MBq
131I already corresponds
with 190.7 pmol
127I and 61.4 pmol
131I.
In the third set,
124I-L19-SIP was synthesized for PET
studies. The labelling was carried out with X is 142 µl
(175 µg, 2.33 nmol) L19-SIP; Y was 90 µl
124I solution
(38.5 MBq, 232 pmol NaI).
Analyses
All conjugates were analysed by instant thin-layer chroma-
tography (ITLC) and HPLC, by SDS-polyacrylamide gel
electrophoresis (PAGE) followed by phosphor imager
analysis for integrity, and by a cell-binding assay for
immunoreactivity.
HPLC monitoring of the final product was performed on
a Jasco HPLC system using a Superdex™ 200 10/300 GL
size exclusion column (GE Healthcare Life Sciences,
Piscataway, NJ, USA). As eluent a mixture of 0.05 M
sodium phosphate and 0.15 M sodium chloride (pH 6.8)
was used at a flow rate of 0.5 ml/min.
ITLC analysis of radiolabelled antibodies was carried
out on silica gel-impregnated glass fibre sheets (Gelman
Sciences, Ann Arbor, MI, USA). As mobile phase, 20 mM
citrate buffer, pH 5.0 was used. The integrity of the
radioimmunoconjugates was monitored by electrophoresis
on a Phastgel System (Pharmacia Biotech, Piscataway, NJ,
USA), using preformed high-density SDS-PAGE gels under
non-reducing conditions. Analysis and quantification of the
radioactivity in the bands was performed with the use of
Phosphor Imager screens and subsequent scanning by a
Phosphor Imager (B&L-Isogen Service Laboratory,
Amsterdam, The Netherlands).
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were determined in an immunoreactivity assay essentially
as described before [11], using ED-B-coated Sepharose
resin in phosphate-buffered saline (PBS) containing 1%
bovine serum albumin (BSA). Five serial dilutions, ranging
from 100 to 6.2 μl resin per tube, were prepared in triplicate
in PBS/1% BSA. L19-SIP (125 ng), labelled with
124Io r
131I, was added to the tubes and the samples were incubated
overnight at 4°C for binding. Excess unlabelled L19-SIP
antibody (10 μg per tube) was added to a second set of
tubes with the lowest concentration of resin to determine non-
specific binding. After incubation, resin was spun down and
radioactivity in the pellet and supernatant was determined in a
gamma counter and the percentage bound and free radioac-
tivity was calculated. Binding data were graphically analysed
in a modified Lineweaver-Burk plot and the immunoreactive
fraction was determined by linear extrapolation to conditions
representing infinite antigen excess.
Biodistribution studies
For the biodistribution experiments with L19-SIP, nude
mice bearing the subcutaneously implanted human head
and neck squamous cell carcinoma (HNSCC) xenograft line
FaDu were used. No control SIP constructs were included
in the current evaluations, because previous studies had
shown the specificity of L19-SIP for targeting of ED-B-
expressing tumours in a direct comparison with the control
D1.3-SIP directed against hen egg white lysosyme [9].
Female mice (Hsd athymic nu/nu,2 5 –32 g; Harlan CPB)
were 8–10 weeks old at the time of the experiments. Animal
experiments were performed according to National Institutes
of Health principles of laboratory animal care and Dutch
National Law (Wet op de dierproeven, Stb 1985, 336).
At t=0, FaDu-bearing nude mice (n=20) received 25 µg
of L19-SIP including 0.37 MBq of
124I-labelled format and
0.37 MBq of
131I-labelled format, by i.v. injection in the
retro-orbital plexus. Two days before the experiments, 0.1%
of potassium iodide was added to the drinking water to
block thyroid uptake of
124I/
131I. For assessment of
biodistribution, four mice containing two tumours each
were sacrificed at 3, 6, 24, 48 and 72 h after injection. All
animals were anaesthetized, bled, killed and dissected.
Besides the tumours, the following organs were removed:
tongue, sternum, heart, lung, liver, spleen, kidney, bladder,
muscle, colon, ileum and stomach. Also stomach contents
were retained. After blood, tumour, normal tissues and
stomach contents were weighed, the amount of radioactivity
in each was counted in a gamma counter (Wallac LKB-
CompuGamma 1282, Kabi Pharmacia, Woerden, The
Netherlands), using the corresponding window settings for
124Ia n d
131I (for the 603 keV and 364 keV gamma energy,
respectively). In this dual-isotope biodistribution study,
cross-over corrections from one radionuclide into the
alternate window were automatically performed using a
standard of each radionuclide. Radioactivity uptake was
calculated as the percentage of the injected dose per gram of
tissue (%ID/g), corrected for radioactive decay.
The mean tumour size of eight tumours at dissection was
234±204, 384±192, 273±144, 371±213 and 315±
201 mm
3 for the groups to be dissected at 3, 6, 24, 48
and 72 h after injection, respectively.
PET imaging procedures
Two animal PET studies for imaging of tumour targeting
with
124I-L19-SIP were performed essentially as described
by Verel et al. [21]. During scanning mice were placed on a
temperature controlled animal bed. In the first experiment,
but not in the second experiment, 0.1% of potassium iodide
was added to the drinking water to block thyroid uptake of
124I. PET studies were performed using a double crystal
layer HRRT PET scanner (Siemens/CTI, Knoxville, TN,
USA), a dedicated small animal and human brain scanner
[24] with a spatial resolution transaxial between 2.3 and 3.2
full-width at half-maximum (FWHM) and in axial direction
between 2.5 and 3.4 FWHM. A detailed description of the
performance of the scanner and the software is given by De
Jong et al. [24]. Transmission scans for attenuation and
scatter correction were routinely obtained with each scan in
two-dimensional mode using a single point
137Cs source.
Three-dimensional emission scans were acquired in 64-bit
list mode during 60 min using a 400–650 keV window. The
64-bit list mode file was first converted into a single-frame
sinogram using a span of 9, and subsequently reconstructed
using a 3-D ANW-OSEM reconstructionwith 2 iterations and
16 subsets and matrix size 256×256 including corrections for
normalization, decay and dead time. 3-D ANW-OSEM is a
3-D attenuation and normalization weighted ordered subset
expectation maximalization reconstruction [25].
In a first PET imaging study, three FaDu xenograft-
b e a r i n gn u d em i c ew e r ei n j e c t e di . v .w i t h3 . 7M B q
124I-L19-SIP (25 µg). The mean tumour size at the start
of the experiment was 266±158 mm
3. During scanning at 1
and 2 days p.i., the animals were sedated using isoflurane.
Because of clear tumour visualization in the first experi-
ment, a second PET imaging experiment was performed to
determine at which stage of tumour development tumours can
bereadilyimagedby
124I-L19-SIP immuno-PET. To this end,
at 1, 2 and 3 weeks after subcutaneous tumour implantation,
six mice were injected i.v. with 3.7 MBq
124I-L19-SIP
(25 µg) and imaged 48 h after each injection. Before each
PET imaging procedure, the size of the tumours was
measured with callipers. Because of inaccurate measurement
of tumour smaller than 50 mm
3, size of these tumours was
indicated to be <50 mm
3.
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Differences in tissue uptake between coinjected conjugates
were statistically analysed for each time point with Excel
2003 software (Microsoft) using Student’s t test for paired
data. Differences in average tumour volume between the
various groups were statistically analysed for each time
point with Student’s t test for unpaired data. Two-sided
significance levels were calculated, and p<0.01 was
considered statistically significant.
Results
GMP-compliant production of
124I
Productionof
124Iv i a
124Te(p,n)
124I reaction at incident energy
of 12.5 MeV resulted in an average target yield (n=15) of
15.4±0.5 MBq/μAh at the end of bombardment (EOB).
During typical commercial runs, bombardment durations of
8ha t1 8µ Ar e s u l t e di nay i e l do f2 . 2G B q
124Ii n - t a r g e t .
Subsequent dry distillation resulted in >90% recovery of
radioiodine from the TeO2 target into the 50 mM NaOH
solution, while less than 0.5% TeO2 was lost from the target.
To allow for GMP-compliant harvesting of
124I, the TERIMO
module was localized in a hot cell integrated in a clean room
meeting GMP conditions (GMP grade C). Visual inspection of
the final product always revealed a clear, colourless solution.
The radiochemical purity as assessed by HPLC analysis was
>99.6% (specification for release >95% as iodide). After
storage for 11 days, the radiochemical purity was still greater
than 99.5%. Three days after production (considered the time
of application) the radionuclidic purity was 99.6±0.06%,
fulfilling the specification for release (>99.0%). The main
radionuclidic contaminants were
123I (<0.5%) and
125I
(<0.03%); other radionuclidic impurities, if any, were below
detectionlimit.Thetelluriumcontentofthe
124I-NaOH solution
was 6±1.6 ng/ml (specification for release <1 μg/ml). The
endotoxin levels were <1.5 EU/ml (specification for release
<5 EU/ml).
Radiolabelling
Despite being >99% in the iodide form, the overall
labelling yield of L19-SIP with
124I produced in house
was only at around 50%. This low labelling yield is
inherent to the fact that
124I is carrier free, and not because
the oxidative power of 25 μg vial-coated IODO-GEN is
insufficient (25 μg IODO-GEN=57 nmol and corresponds
to 228 nmol N-Cl groups). In the presence of the excessive
amount of 6.7 nmol NaI the
124I labelling yield was 96%
upon using the same amount of L19-SIP (100 μg,
1.33 nmol) and the same amount (25 μg vial-coated)
IODO-GEN. For a study on the fine tuning of I/MAb molar
ratios, the labelling of L19-SIP was evaluated in relation to
the amount of NaI present during labelling. Figure 1 shows
that in the presence of 200 pmol NaI or more, the labelling
efficiency was 85–95%. It is of note that the same data as
shown in Fig. 1 were also obtained when cetuximab was
used as a model substrate (data not shown).
For the biodistribution study, the amount of NaI was
selected in such a way that the I/MAb of the
124I product
was the same as that of the
131I product. As a result, the
I/MAb molar ratio of both resulting conjugates was about
1:10. For the subsequent
124I animal PET studies the same
I/MAb molar ratio was created. The radiochemical purity of
the injected products was 99.9% for
124I-L19-SIP as well as
for
131I-L19-SIP. Phosphor imager analysis of SDS-PAGE
gels as well as HPLC analysis revealed optimal integrity of
the antibody. The immunoreactivity of
124I-L19-SIP was
93.1±4.2% at the highest resin concentration and 100% at
infinite antigen excess (for
131I-L19-SIP these figures were
89.6 and 100%, respectively).
Biodistribution in tumour-bearing nude mice
For comparison of the biodistribution of
124I- and
131I-L19-
SIP in tumour-bearing nude mice, both conjugates were
coinjected. At 3, 6, 24, 48 and 72 h after injection, the
average uptake (%ID/g, mean ± SEM) in tumour, blood,
normal tissues and gastrointestinal contents was determined
and shown in Fig. 2 for a selected panel of tissues. Blood
values were similar for both conjugates at all time points,
indicating that (1) radiolabelling had not differentially altered
the pharmacokinetics of the antibody, and (2) serum stability
was comparable for both conjugates. There was no signif-
icant difference in uptake of
124Ia n d
131I in the majority of
normal organs (differences indicated by asterisk in Fig. 2).
Tumour uptake of
124I was 7.3±2.1, 10.8±1.5, 7.8±1.4,
5.3±0.6 and 3.1±0.4%ID/g tissue at 3, 6, 24, 48 and 72 h
Fig. 1 Labelling of L19-SIP with
124I: labelling efficiency in relation
to the amount of NaI carrier added. Labelling efficiency was assessed
by ITLC
Eur J Nucl Med Mol Imaging (2009) 36:1235–1244 1239p.i.. In comparison,
131I levels at these time points were
7.3±2.0, 10.4±1.4, 7.4±1.2, 5.0±0.5 and 2.7±0.4%ID/g,
respectively. From 6 h p.i. onwards,
124I-L19-SIP uptake in
tumours was higher than in any normal organ or tissue.
During the same period, blood levels decreased from 14.0±
2.7%ID/g at 3 h after injection to 0.08±0.03%ID/g at 72 h
after injection. This resulted in very favourable tumour to
blood ratios at later time points ranging from 6.0 at 24 h p.i.
to 45.9 at 72 h p.i. (Table 1). Also tumour to normal tissue
ratios were relatively high from 24 h after injection
onwards, for most organs exceeding the value 4 (Table 1).
Rapid blood clearance during the first 24 h was accompa-
nied by high radioactivity uptake in kidney, stomach and
stomach contents. This is indicative of rapid renal excretion
and catabolism of the conjugate with partial reabsorption of
124I metabolites, which can accumulate in the stomach and
are released from the body via intestines and colon.
PET imaging with
124I-L19-SIP in tumour-bearing nude
mice
Immuno-PET with
124I-L19-SIP revealed clear delineation
of the tumours at 24 h p.i. (Fig. 3a). In addition, slight
uptake was visible in the stomach region, as was previously
observed in the biodistribution experiments (Fig. 2). Prom-
inent uptake of radioactivity was also observed in the
bladder region, and from this single scan it was not clear
whether uptake was due to targeting of ED-B-expressing
normal tissues by
124I-L19-SIP (e.g. endometrium and
ovary) or due to excretion of
124I-containing catabolites
via the urine. Later scans of the same tumour-bearing nude
mice at 48 h p.i., however, showed only clear retention of
124I-L19-SIP in the tumours (Fig. 3b). This observation
confirms that temporarily high levels of
124I in the stomach
regions were related to the presence of catabolites of
124I-L19-SIP and/or free iodine.
Since tumour size in the previous imaging experiment
was relatively large, 266±158 mm
3 at the time of conjugate
injection, we examined how early after transplantation
FaDu tumours can be visualized. To this end, at 1, 2 and
3 weeks after transplantation of the FaDu tumours a freshly
produced
124I-L19-SIP sample was injected, and 48 h later
an imaging procedure was performed. As illustrated by
Fig. 4, tumour delineation was possible from 1 week after
implantation onwards, when tumour size was still
<50 mm
3.
Fig. 2 Biodistribution of coin-
jected
124I-L19-SIP (0.37 MBq)
(a) and
131I-L19-SIP
(0.37 MBq) (b) in FaDu
xenograft-bearing nude mice at
3, 6, 24, 48 and 72 h after
intravenous injection. Significant
differences in uptake of the
conjugates are marked with an
asterisk. Data are presented as
average of four animals and
standard deviation
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Molecular imaging of tumour angiogenesis, one of the
hallmarks of cancer, has clinical perspectives for lesion
detection, patient stratification, new drug development and
validation, treatment monitoring and dose optimization
[26]. To date, the application of PET for imaging of tumour
vasculature has mostly exploited the use of radiolabelled
RGD peptides for imaging of integrin αvβ3 expression, and
radiolabelled peptides and MAbs for imaging VEGF/
VEGFR expression [26]. Most recently the antibody
fragment L19-SIP, directed against the ED-B domain of
fibronectin, was identified as another attractive candidate
for imaging of tumour vasculature, particularly because of its
high and prolonged uptake in angiogenic tumour vessels and
limited uptake in non-target organs. These targeting charac-
teristics make L19-SIP, when armed with toxic payloads,
also a promising ligand for therapy. Radioimmunotherapy is
among the most advanced therapeutic approaches in the
clinical development of L19-SIP, and for this purpose the
antibody fragment is radiolabelled with
131I[ 13].
After introduction of
131I- and
99mTc-labelled derivatives
of L19 for SPECT imaging of tumour angiogenesis [27,
28], in 2007 the first PET imaging derivative of L19-SIP
was described:
76Br-L19-SIP [17]. Besides clear tumour
targeting,
76Br-L19-SIP also showed persistent activity in
blood, stomach and several other normal organs, most
probably due to in vivo debromination. The
76Br-L19-SIP
conjugates used in these studies were slightly less stable
and immunoreactive than corresponding
125I-L19-SIP con-
jugates and appeared vulnerable for aggregate formation.
The formation of free
76Br
− due to catabolism, and its
prolonged retention in blood, was also observed by
Lövqvist et al., who compared the biodistribution of the
76Br-38S1 and
125I-38S1 antibody conjugates in tumour-
bearing nude mice [29]. The aforementioned studies
revealed that
76Br cannot be used as a PET radionuclide
substitute for iodine radioisotopes. Another limitation of
76Br is its limited availability and the lack of supply of
clinical grade
76Br. Limited availability of long-lived
positron emitters for immuno-PET made us decide a few
years ago to put effort into the large-scale GMP production
of
89Zr (to be used for internalizing MAbs) and
124I (to be
used for non-internalizing MAbs) and into the development
of standardized and easy-to-use radiolabelling procedures
Fig. 3 PET images of FaDu xenograft-bearing nude mouse injected
with
124I-L19-SIP (3.7 MBq, 25 μg). Coronal images were acquired at
24 (a) and 48 h (b) after injection. Image planes have been chosen
where both tumours were visible. Uptake of
124I in the stomach
(arrow) and to some extend in bladder (urine) is visible at 24 h p.i.,
but has disappeared at 48 h p.i.
Table 1 Tumour to normal tissue ratios of coinjected
124I-L19-SIP
and
131I-L19-SIP in FaDu xenograft-bearing nude mice
Biodistribution time 3h 6h 24h 48h 72h
Tumour to tissue ratios of
124I-L19-SIP
Blood 0.49 1.07 6.04 15.00 45.90
Tongue 1.11 1.69 4.14 5.84 14.76
Sternum 2.20 3.74 9.65 13.19 20.37
Heart 1.23 2.43 12.39 28.69 75.36
Lung 1.18 1.65 6.72 12.09 25.61
Liver 2.07 4.44 18.50 46.73 96.01
Spleen 1.80 3.37 11.48 27.95 53.25
Kidney 0.69 1.42 6.15 14.26 31.30
Bladder 1.80 1.96 1.83 3.72 9.99
Muscle 5.49 8.24 22.57 49.97 118.89
Colon 2.72 2.99 4.44 3.25 3.92
Ileum 1.58 2.71 4.90 5.85 4.80
Stomach 1.49 1.84 7.22 7.13 11.62
Stomach contents 1.23 1.98 15.83 9.86 24.92
Tumour to tissue ratios of
131I-L19-SIP
Blood 0.48 1.00 5.45 13.54 43.44
Tongue 1.09 1.61 4.34 6.13 15.40
Sternum 2.12 3.39 9.24 12.54 20.49
Heart 1.20 2.23 11.39 27.44 59.17
Lung 1.17 1.55 6.31 11.52 22.06
Liver 2.08 4.16 16.92 41.59 81.63
Spleen 1.84 3.28 11.32 26.23 50.53
Kidney 0.68 1.30 5.50 12.06 27.88
Bladder 1.73 1.81 1.73 4.23 8.57
Muscle 5.26 7.60 21.65 45.77 103.17
Colon 2.66 2.78 4.25 3.31 5.27
Ileum 1.62 2.73 5.42 6.56 5.47
Stomach 1.41 1.73 7.01 7.32 12.67
Stomach contents 1.17 1.83 14.50 9.53 22.88
Biodistribution assessed at 3, 6, 24, 48 and 72 h after intravenous
injection. Data are presented as average of four animals. Data derived
from Fig. 2
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trials [15].
In the present study, we aimed at the development of
124I-L19-SIP immuno-PET, not only for imaging of tumour
angiogenesis, but also as a scouting procedure prior to
clinical
131I-L19-SIP RIT, to confirm selective tumour
targeting and to enable dosimetry. We considered
124It o
be the most suitable positron emitter for these applications
(see “Introduction” section), but realized that availability of
clinical grade
124I would be a problem. The urgent need for
this positron emitter also became clear from a survey
performed in 2005, in which the expectations of European
researchers in terms of innovative radionuclides was
evaluated [30]. A questionnaire was sent to 134 nuclear
medicine centres in Europe, and the 54 responding centres
expressed the strongest interest in the availability of
124I.
This made us decide to make the production of large
batches of clinical grade
124I the starting point of the
present studies. As demonstrated herein, infrastructure and
procedures were developed for efficient GMP-compliant
production of large batches of
124I (>2 GBq) at high
radionuclidic (>99.0%) and radiochemical (>95% as
iodide) purity and low tellurium (<1 μg/ml) and endotoxin
(<1.5 EU/ml) content.
Although labelling with radioiodine isotopes has been a
widespread practice for decades, in several studies
124I-labelled compounds were damaged and obtained in
low yields [31–34]. Herein, L19-SIP was labelled with
124I
according to a direct labelling method with the use of a low
amount of the mild oxidant IODO-GEN, and taking the
I/MAb molar ratio and interference of radiolytic processes
into account to arrive at optimal quality
124I-L19-SIP
conjugates. As convincingly shown by Fig. 1, addition of
NaI as carrier to the reaction mixture during
124I labelling
provides a means to increase the labelling yield with this
precious isotope. This carrier approach was found to be
generally applicable. Of course, caution should be taken
when applying these procedures for MAbs containing an
overabundance of tyrosines in the complementarity-
determining regions (CDR), so when the I/MAb molar
ratio may be the prime parameter for immunoreactivity
[35]. In that case, even single iodine incorporation on a
tyrosinemoietyinCDRmightdestroytheimmunoreactivityof
the MAb molecule owing to the bulkiness of the ion atom and/
or change in pKa value of the tyrosine moiety (from 10.00 to
8.51). Therefore, in this study we decided to take the I/MAb
ratio not higher than strictly necessary for obtaining high
labelling yields and optimal immunoreactivity. However,
Fig. 4 Serial PET images of
FaDu xenograft-bearing nude
mouse injected with
124I-L19-
SIP (3.7 MBq, 25 μg). At 1
(a, d), 2 (b, e) and 3 (c, f) weeks
after tumour implantation
124I-L19-SIP was administered,
and 48 h later coronal images
were acquired. Image planes
have been chosen where the left
tumour (upper panel, a–c)o r
right tumour (lower panel, d–f)
is optimally visible. In contrast
to Fig. 3, the thyroid (arrow)i s
visible because this organ was
not blocked by potassium iodide
in this experiment
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131I-MAb conjugate in RIT, the I/MAb molar ratios of the
conjugates can be easily synchronized, since this provides the
best guarantee that the biodistribution of the therapeutic agent
will be accurately predicted by the scouting agent. As another
precaution to obtain optimal quality conjugates, immediately
after radiolabelling ascorbic acid was added to the reaction
mixture to reduce the IODO-GEN and to protect the L19-SIP
against radiation damage.
L19-SIP labelled with
124I according to the aforemen-
tioned procedures demonstrated optimal integrity and
immunoreactivity, and exhibited the same pharmacokinetic
behaviour as the corresponding
131I conjugate. Moreover,
biodistribution studies revealed high and selective tumour
targeting, resulting in tumour to blood ratios ranging from
6.0 at 24 h to 45.9 at 72 h p.i.. Normal tissue accumulation
of
124I-L19-SIP was significantly lower than previously
reported for
76Br-L19-SIP. For example, while
76Br-L19-
SIP showed blood levels of 7.6±1.8 and 8.1±1.7%ID/g at
24 and 48 h p.i., respectively, for
124I-L19-SIP these values
were 1.37±0.43 and 0.37±0.07, respectively. As a result,
high tumour to normal tissue ratios were obtained with
124I-L19-SIP, resulting in clear visualization of tumours by
PET imaging, even when tumours were small (∼50 mm
3).
These achievements will open new possibilities for
124I immuno-PET in general, and for PET imaging of
tumour angiogenesis with
124I-L19-SIP in particular.
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